ACG expands its footprint in Brazil
ACG Group has expanded its footprint in Brazil with the launch of its new capsules manufacturing plant in Pouso Alegre-Minas Gerais.
20 Feb 2019 | By Abhishek Muralidharan
The USD 94-mn factory spans an area of 14,000 sq metres and is projected to generate around 500 new jobs locally.
Selwyn Noronha, CEO, ACG Capsules, said, “ACG Capsules is one of the largest capsule manufacturers in the world, servicing pharmaceutical and nutraceutical customers in more than 100 countries. The company already has a significant presence in Latin America, and following this investment, ACG will further be able to meet the growing requirements of the region.”
With this investment, ACG has established its second manufacturing facility in Latin America, after the acquisition of Nova Nordeplast in 2017.
The new facility complies with the standards defined by the Brazilian health regulatory agency ANVISA and GMP regulatory bodies.
Both, Nova Nordeplast and the new capsule plant will enable ACG to offer faster response times to its customers in the same region and to its neighbouring countries.
ACG Capsules has also pioneered printing on hard capsules that allows the pharmaceutical companies to create brand differentiation in the market and thwart the threat of counterfeit or falsified drugs.
Roberson Petrungaro, commercial director – Latin America, ACG Capsules, said, “ACG is extremely proud of this new state-of-the-art facility, which demonstrates our long-term commitment to Brazil. As the fifth largest pharmaceutical market in the world, Brazil is a key strategic one for ACG. And the benefit of having local manufacturing will certainly strengthen ties with our customers.”
ACG consists of another operation arm in Brazil known as the ACG Films & Foils, which is located in the state of São Paulo, in the city of Cotia. This unit caters to the pharmaceutical, food & FMCG industry.
It offers specialised primary pharmaceutical packaging including aluminium-based range, special packaging films, high barrier, and polymer films, with all the products being in compliance with FDA, Europe Pharmacopeia and CFDA standards.